Should You Invest in SpringWorks Therapeutics Inc Stock on Friday?
December 14, 2023
🌥️Trending News
SPRINGWORKS ($NASDAQ:SWTX): Is investing in SpringWorks Therapeutics Inc stock a good idea for your portfolio on Friday? SpringWorks Therapeutics Inc is a biopharmaceutical company that focuses on developing therapies to improve the lives of people with rare diseases. They are committed to discovering treatments for rare diseases that have historically been neglected or difficult to address. The company is led by a team of experienced and passionate individuals with a strong track record of success in developing treatments for rare diseases. SpringWorks Therapeutics Inc has seen an impressive performance in the stock market over the past few months, and many investors are considering adding it to their portfolios. They have a solid balance sheet with strong financials, and their pipeline of treatments is promising.
In addition, the company is actively partnering with other biotechnology companies to expand their research and development efforts. The company has been performing well in the stock market and has a promising pipeline of treatments that could lead to significant breakthroughs in treating rare diseases. In addition, their strong financials and partnerships with other biotechnology companies are both reassuring for investors.
Market Price
The stock of SpringWorks Therapeutics Inc has been relatively stable over the last week, opening at $31.3 on Monday and closing at $31.0 on Friday, a decrease of 1.6% from its last closing price of $31.5. This suggests that the stock may not be a great option for investors looking for quick returns. However, if investors are looking for a longer term investment, SpringWorks Therapeutics Inc may be worth considering. The company has a strong portfolio of drugs and treatments in development, and could potentially offer a great return on investment in the long run. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Springworks Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 0 | -304.96 | -130.2% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Springworks Therapeutics. More…
| Operations | Investing | Financing |
| -214.29 | -161.05 | -2.13 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Springworks Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 467.65 | 72.75 | 6.31 |
Key Ratios Snapshot
Some of the financial key ratios for Springworks Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 0.0% | – | -132.4% |
| FCF Margin | ROE | ROA |
| -93.8% | -47.7% | -43.2% |
Analysis
GoodWhale has performed an analysis of SPRINGWORKS THERAPEUTICS‘s financials and classified it as an ‘elephant’, a type of company which is rich in assets after deducting off liabilities. According to our findings, SPRINGWORKS THERAPEUTICS is strong in asset, but weak in dividend, growth, and profitability. Additionally, the company has an intermediate health score of 5/10 with regard to its cashflows and debt, which indicates that it may be able to sustain future operations in times of crisis. With this information, investors who are looking for a company rich in assets may be interested in SPRINGWORKS THERAPEUTICS. However, investors who prioritize dividend, growth, and profitability may want to look elsewhere. More…
Peers
The company is focused on developing and commercializing therapies for the treatment of rare and underserved diseases. SpringWorks Therapeutics Inc’s competitors include Aadi Bioscience Inc, Avalo Therapeutics Inc, and Immunic Inc.
– Aadi Bioscience Inc ($NASDAQ:AADI)
Aadi Bioscience Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of small molecule drugs for the treatment of cancer and other diseases. The company’s lead product candidate is AB-101, a small molecule inhibitor of the PI3K/mTOR pathway, which is in Phase I clinical trials for the treatment of solid tumors. Aadi Bioscience Inc has a market cap of 317.87M as of 2022, a Return on Equity of -28.05%.
– Avalo Therapeutics Inc ($NASDAQ:AVTX)
Avalo Therapeutics Inc is a clinical stage biopharmaceutical company developing novel cancer therapies. The company’s market cap as of 2022 is 50.93M and its ROE is 729.23%. Avalo’s pipeline of products includes two clinical stage programs: AVL-292, a first-in-class, small molecule inhibitor of checkpoint kinase 1 (Chk1) for the treatment of solid tumors, and AVL-181, a first-in-class, small molecule inhibitor of checkpoint kinase 2 (Chk2) for the treatment of hematologic malignancies.
– Immunic Inc ($NASDAQ:IMUX)
Immunic, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing oral therapies for the treatment of immune-mediated diseases. Its pipeline includes IMU-838 that is in Phase II clinical trial for the treatment of plaque psoriasis and atopic dermatitis; and IMU-935, which is in Phase I clinical trial for the treatment of autoimmune diseases. The company was founded by Daniel M. Adelman, Michael J. Brenner and William T. Symonds on December 15, 2006 and is headquartered in New York, NY.
Summary
SpringWorks Therapeutics Inc is a biopharmaceutical company focused on the development of new treatments and cures for rare diseases. The company has a strong pipeline of potential treatments, and has collaborated with a number of pharmaceutical companies to develop these treatments. According to Zacks Investment Research, SpringWorks Therapeutics has a Neutral rating, as analysts expect the company’s earnings growth to outpace the industry average. Despite this, the stock is undervalued compared to its competitors and therefore could prove to be a good investment for long term investors.
